Navigation Links
Biocon and Pfizer Enter Into Global Commercialization Agreement
Date:10/18/2010

BANGALORE, India and NEW YORK, Oct. 18 /PRNewswire/ -- Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, today announced that they have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products:  Recombinant Human Insulin, Glargine, Aspart and Lispro.  Pfizer will have exclusive rights to commercialize these products globally, with certain exceptions, including co-exclusive rights for all of the products with Biocon in Germany, India and Malaysia.  Pfizer will also have co-exclusive rights with existing Biocon licensees with respect to some of the products, primarily in a number of developing markets.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

Biocon will remain responsible for the clinical development, manufacture and supply of these biosimilar Insulin products, as well as for regulatory activities to secure approval for these products in various geographies.  Biocon's Recombinant Human Insulin formulations are approved in 27 countries in developing markets, and commercialized in 23, while Glargine has been launched in its first market, India.  

Under the terms of the agreement, Pfizer will make upfront payments totaling $200 million.  Biocon is also eligible to receive additional development and regulatory milestone payments of up to $150 million and will receive additional payments linked to Pfizer's sales of its four Insulin biosimilar products across global markets.

DIABETES: A GLOBAL PANDEMIC

Diabetes is one of the fastest-growing and largest disease burdens globally, with nearly 230 million diabetic patients worldwide and 3 million deaths attributed to the
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
2. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
3. Pfizer Completed Acquisition of FoldRx
4. Pfizer To Review Strategic Alternatives For Capsugel
5. Pfizer Offers First 500,000 Consumers Free Advil® to Launch Medicine Cabinet Cleanout Campaign
6. Pfizer Invites Public to View and Listen to Webcast of November 2 Conference Call With Analysts
7. Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer
8. Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
9. Reportlinker Adds Pfizer Inc.: PharmaVitae Profile
10. Amgen and Pfizer Introduce Psophisticated Style: A Guide to Everyday Style and Psoriasis™ Hosted by Tim Gunn
11. Pfizer to Acquire FoldRx Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
(Date:7/22/2014)...  According to the American Optometric Association (AOA), parents ... devices. An AOA survey reports that 83 percent of ... they use an electronic device for three or more ... parents revealed that only 40 percent of parents believe ... amount of time. Eye doctors are concerned that this ...
(Date:7/22/2014)... MARCOS, Texas , July 22, 2014 Quantum Materials ... and Mr. John Heaton to the Board of ... by Dr. Ghassan Jabbour , QMC Chief Science Officer and ... Michael Wong of Rice University and Mr. Tomio ... Japan . " Quantum Materials welcomes ...
Breaking Medicine Technology:Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... Pharmaceuticals, Inc. announced today that the U.S. Food ... drug status for the treatment of pancreatic cancer. ... the marketed chemotherapy drug irinotecan.  MM-398 is partnered ... Taiwan under the designation PEP02. (Logo: ...
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced ... the NASDAQ Global Select Market closes on Tuesday, August 9, ... Executive Officer, will host a conference call and webcast at ... the financial results for the second quarter 2011 and to ...
Cached Medicine Technology:FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 3
(Date:7/22/2014)... 2014 Air Conditioning & Heating Inc. ... authorized Daikin comfort pro dealer. This means that the ... and cooling system equipment. Only a select few businesses ... before being approved. , Daikin co-developed an R-410A refrigerant ... System Air Conditioning Market. They are also the inventor ...
(Date:7/22/2014)... July 22, 2014 Dr. Dental is excited ... patients and new visitors in mind, one of the main ... visual layout that makes navigation very easy. Dr. Dental is ... of going to the dentist affordable, convenient and fun, and ... new feature is an appointment scheduling system right on the ...
(Date:7/22/2014)... CA (PRWEB) July 22, 2014 Dr. ... with his surgical colleagues, have recently discussed the reasons ... Many leaders in the periodontics profession are seeing the ... go up exponentially. In fact, one surgeon reported that ... failing implants. Although dental implants have a very high ...
(Date:7/22/2014)... The 2014 Warrior-Family Symposium (WFS) ... Building and International Trade Center in Washington, D.C. ... Civilian Communities,” will be held from 8:30 a.m. ... and cohosted by the Military Officers Association of ... (NDIA). USAA is the Executive Sponsor of the ...
(Date:7/22/2014)... United Benefit Advisors (UBA), the nation's leading ... an insurance veteran with more than 15 years of ... based in the company's Chicago office. , UBA Board ... chose to accept this important, strategic position with UBA. ... challenges facing UBA and its Partners as we move ...
Breaking Medicine News(10 mins):Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Dr. Dental Reveals Exciting New Website 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 3Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5
... as soon as possible, researchers say , MONDAY, May ... breast lesions found in women with a high risk ... suggest. , An indeterminate breast lesion is one that ... women include those who have breast cancer, a history ...
... urged to consider risks of hormone treatment, inform patients ... widely used class of prostate cancer drugs called gonadotropin-releasing ... attack, stroke and sudden death in men, a U.S. ... on initial findings from a preliminary and ongoing analysis ...
... While timely care can reduce stress among breast cancer ... compromise other factors important to care, such as safety, effectiveness, ... the April issue of the Journal of the American ... cancer diagnosis and one in eight women will receive ...
... States will have an osteoporosis-related fracture in her lifetime (1). ... 2010 issue of the Journal of the American Academy ... women will be tested and treated for osteoporosis, which if ... fractures. "Less than 10 percent of patients who sustain ...
... ... Medical Group, a Torrance, California-based healthcare organization, today announced the acquisition of Talbert ... managed care patients in Los Angeles County and Orange County, California. , ... Torrance, CA ...
... key, study finds , MONDAY, May 3 (HealthDay News) ... their children from becoming bullies by helping them with ... study suggests. , "Improving parent-child communication and parental ... on child bullying," said study author Dr. Rashmi Shetgiri, ...
Cached Medicine News:Health News:Aggressive Action Urged When Evaluating Breast Lesions 2Health News:FDA Reviews Side Effects From Prostate Cancer Therapy 2Health News:Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment 2Health News:Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment 3Health News:Women want answers, but what questions should be asked? 2Health News:Women want answers, but what questions should be asked? 3Health News:HealthCare Partners Medical Group Expands to Orange County. HealthCare Partners and Talbert Medical Group Join Forces 2Health News:HealthCare Partners Medical Group Expands to Orange County. HealthCare Partners and Talbert Medical Group Join Forces 3Health News:Involved Parents Less Likely to Raise Bullies 2
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... kit measures the biologically active form ... is a valuable prognostic marker for cardiovascular ... plasma vitamin B6 level and Coronary Heart ... reactions of homocysteine to cystathionine and then ...
... volume for use with 4, 8, or 12 ... withdrawal of nearly all of the solution. Corners ... Made of natural virgin polystyrene containing no regrinds. ... by irradiation. Dimensions: 78 mm W x 152 ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
Medicine Products: